Aldeyra Therapeutics Inc ALDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALDX is a good fit for your portfolio.
News
-
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
-
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
-
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
-
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment
-
Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option
-
Aldeyra Shares Rally After AbbVie Licensing Deal on Eye Drug
Trading Information
- Previous Close Price
- $3.91
- Day Range
- $3.88–4.00
- 52-Week Range
- $1.42–11.97
- Bid/Ask
- $3.89 / $4.11
- Market Cap
- $234.09 Mil
- Volume/Avg
- 600 / 593,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.aldeyra.com
Comparables
Valuation
|
Metric
|
ALDX
|
VRDN
|
KROS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.97 | 2.99 | 5.39 |
Price/Sales | — | 1,857.18 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALDX
|
VRDN
|
KROS
|
|---|---|---|---|
Quick Ratio | 6.42 | 17.93 | 13.63 |
Current Ratio | 6.64 | 18.26 | 14.25 |
Interest Coverage | −20.66 | −137.76 | — |
Quick Ratio
ALDX
VRDN
KROS
Profitability
|
Metric
|
ALDX
|
VRDN
|
KROS
|
|---|---|---|---|
Return on Assets (Normalized) | −19.85% | −42.76% | −35.62% |
Return on Equity (Normalized) | −24.05% | −82.42% | −39.15% |
Return on Invested Capital (Normalized) | −24.99% | −50.70% | −41.95% |
Return on Assets
ALDX
VRDN
KROS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ppbczmtpdx | Ywmw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xqwndldsz | Qgxlnx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tqqmchbz | Dkpcwx | $99.5 Bil | |
MRNA
| Moderna Inc | Dgzwklmr | Fkjh | $38.8 Bil | |
ARGX
| argenx SE ADR | Rrcmjfxm | Dmtt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wjwvdxhkp | Hbb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mhlmgfm | Lwsvls | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dpbfrrjf | Dsdwfz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qsqljjpmp | Brmlfvj | $12.5 Bil | |
INCY
| Incyte Corp | Hdfqqhrj | Kjcypdf | $11.6 Bil |